Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 375 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatic Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT01817985
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
GS-5816
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

NCT05440344
View directory record Official record
Conditions
Hepatic Insufficiency, Healthy
Interventions
Imlunestrant
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

NCT03818672
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

NCT04276662
View directory record Official record
Conditions
Hepatic Impairment
Interventions
DS-3201b
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

NCT00819468
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

NCT04056468
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

NCT05961397
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Rialto, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tepotinib Hepatic Impairment Trial

NCT03546608
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

NCT05386589
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Molnupiravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Hollywood, Florida • Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

NCT02857868
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABL001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GT-032 Belapectin Hepatic Impairment

NCT04332432
View directory record Official record
Conditions
Hepatic Impairment
Interventions
belapectin
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Rialto, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

NCT07677358
View directory record Official record
Conditions
Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
Interventions
Atirmociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Recruiting Phase 1 Interventional

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

NCT04617522
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor, Liver Failure
Interventions
Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

NCT05391724
View directory record Official record
Conditions
Hepatic Impairment
Interventions
CMX001
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

NCT01767623
View directory record Official record
Conditions
Neoplasms
Interventions
Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

NCT07018492
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795
View directory record Official record
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DZD9008 PK Study in Hepatic Impairment Subjects

NCT06084104
View directory record Official record
Conditions
Hepatic Impairment
Interventions
DZD9008
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

NCT04480827
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

NCT04587622
View directory record Official record
Conditions
Hepatic Failure
Interventions
Icenticaftor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 28, 2026, 11:21 PM EDT